{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:48:13Z","timestamp":1795034893504,"version":"4.10.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yulin City Scientific Research and Technology Development Plan Project","award":["No. 20220634"],"award-info":[{"award-number":["No. 20220634"]}]},{"name":"Yulin City Scientific Research and Technology Development Plan Project","award":["No. 202235023"],"award-info":[{"award-number":["No. 202235023"]}]},{"name":"Guangxi Science and Technology Major Project","award":["GuikeAA22096030"],"award-info":[{"award-number":["GuikeAA22096030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04682-z","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:33:50Z","timestamp":1743716030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical efficacy of sacubitril\/valsartan combined with cardiac rehabilitation in patients with heart failure after acute myocardial infarction: a single-center randomized trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Yan-Mei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Fang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"10","key":"4682_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3760\/cma.j.issn.0253-3758.2019.10.003","volume":"47","author":"Chinese Society of Cardiology of Chinese Medical Association","year":"2019","unstructured":"Chinese Society of Cardiology of Chinese Medical Association. Editorial board of Chinese journal of cardiology. [2019 Chinese society of cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(10):766\u201383. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3758.2019.10.003","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"3","key":"4682_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jchf.2017.09.015","volume":"6","author":"MC Bahit","year":"2018","unstructured":"Bahit MC, Kochar A, Granger CB, Failure P-MIH. JACC Heart Fail. 2018;6(3):179\u201386. https:\/\/doi.org\/10.1016\/j.jchf.2017.09.015.","journal-title":"JACC Heart Fail"},{"issue":"19","key":"4682_CR3","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","volume":"163","author":"CB Granger","year":"2003","unstructured":"Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345\u201353. https:\/\/doi.org\/10.1001\/archinte.163.19.2345.","journal-title":"Arch Intern Med"},{"issue":"18","key":"4682_CR4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA. 1995;273(18):1450\u20136.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"4682_CR5","first-page":"444","volume":"18","author":"S Yusuf","year":"1993","unstructured":"Yusuf S. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure. Herz. 1993;18(Suppl 1):444\u20138.","journal-title":"Herz"},{"issue":"5","key":"4682_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MCA.0000000000000955","volume":"32","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wu Y, Zhang K, Ke Z, Hu P, Jin D. Benefits of early administration of Sacubitril\/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis. 2021;32(5):427\u201331. https:\/\/doi.org\/10.1097\/MCA.0000000000000955.","journal-title":"Coron Artery Dis"},{"issue":"5","key":"4682_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00059-017-4671-1","volume":"44","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M. Sacubitril\/valsartan for heart failure with reduced left ventricular ejection fraction: A retrospective cohort study. Herz. 2019;44(5):425\u201332. https:\/\/doi.org\/10.1007\/s00059-017-4671-1.","journal-title":"Herz"},{"issue":"10","key":"4682_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40273-018-0688-4","volume":"36","author":"A Gandjour","year":"2018","unstructured":"Gandjour A, Ostwald DA, Sacubitril\/Valsartan. (LCZ696): A novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. PharmacoEconomics. 2018;36(10):1285\u201396. https:\/\/doi.org\/10.1007\/s40273-018-0688-4.","journal-title":"PharmacoEconomics"},{"key":"4682_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/164_2016_77","volume":"243","author":"Y Khder","year":"2017","unstructured":"Khder Y, Shi V, McMurray J, Lefkowitz MP. Sacubitril\/Valsartan (LCZ696) in heart failure. Handb Exp Pharmacol. 2017;243:133\u201365. https:\/\/doi.org\/10.1007\/164_2016_77.","journal-title":"Handb Exp Pharmacol"},{"key":"4682_CR10","doi-asserted-by":"publisher","unstructured":"Kommu S, Berg RL. The efficacy and safety of Sacubitril\/Valsartan compared to Valsartan in patients with heart failure and mildly reduced and preserved ejection fractions: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2024;13(6):1572. https:\/\/doi.org\/10.3390\/jcm13061572.","DOI":"10.3390\/jcm13061572"},{"issue":"52","key":"4682_CR11","doi-asserted-by":"publisher","first-page":"e28231","DOI":"10.1097\/MD.0000000000028231","volume":"100","author":"J Lin","year":"2021","unstructured":"Lin J, Zhou J, Xie G, Liu J. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant Article. Med (Baltim). 2021;100(52):e28231. https:\/\/doi.org\/10.1097\/MD.0000000000028231.","journal-title":"Med (Baltim)"},{"key":"4682_CR12","doi-asserted-by":"publisher","first-page":"107424842110586","DOI":"10.1177\/10742484211058681","volume":"27","author":"R Zhang","year":"2022","unstructured":"Zhang R, Sun X, Li Y, He W, Zhu H, Liu B, Zhang A. The efficacy and safety of Sacubitril\/Valsartan in heart failure patients: A review. J Cardiovasc Pharmacol Ther. 2022;27:10742484211058681. https:\/\/doi.org\/10.1177\/10742484211058681.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"11","key":"4682_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin-neprilysin Inhibition versus Enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"key":"4682_CR14","doi-asserted-by":"publisher","unstructured":"Sardu C, Massetti M, Scisciola L, Trotta MC, Santamaria M, Volpicelli M, et al. Angiotensin Receptor\/Neprilysin inhibitor effects in CRTd non-responders: from epigenetic to clinical beside. Pharmacol Res. 2022;182:106303. https:\/\/doi.org\/10.1016\/j.phrs.2022.106303.","DOI":"10.1016\/j.phrs.2022.106303"},{"issue":"2","key":"4682_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.rehab.2014.01.001","volume":"57","author":"R Deniz Acar","year":"2014","unstructured":"Deniz Acar R, Bulut M, Erg\u00fcn S, Yesin M, Al\u0131c\u0131 G, Ak\u00e7akoyun M. Effect of cardiac rehabilitation on left atrial functions in patients with acute myocardial infarction. Ann Phys Rehabil Med. 2014;57(2):105\u201313. https:\/\/doi.org\/10.1016\/j.rehab.2014.01.001.","journal-title":"Ann Phys Rehabil Med"},{"key":"4682_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fphys.2013.00302","volume":"4","author":"HF Jelinek","year":"2013","unstructured":"Jelinek HF, Huang ZQ, Khandoker AH, Chang D, Kiat H. Cardiac rehabilitation outcomes following a 6-week program of PCI and CABG patients. Front Physiol. 2013;4:302. https:\/\/doi.org\/10.3389\/fphys.2013.00302.","journal-title":"Front Physiol"},{"issue":"1","key":"4682_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00008483-200301000-00003","volume":"23","author":"TR McConnell","year":"2003","unstructured":"McConnell TR, Mandak JS, Sykes JS, Fesniak H, Dasgupta H. Exercise training for heart failure patients improves respiratory muscle endurance, exercise tolerance, breathlessness, and quality of life. J Cardiopulm Rehabil. 2003;23(1):10\u20136. https:\/\/doi.org\/10.1097\/00008483-200301000-00003.","journal-title":"J Cardiopulm Rehabil"},{"issue":"3","key":"4682_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MRR.0000000000000229","volume":"40","author":"YJ Tsai","year":"2017","unstructured":"Tsai YJ, Li MH, Chen CH, Tuan SH, Chen YJ, Lin KL. Improved oxygen uptake efficiency slope in acute myocardial infarction patients after early phase I cardiac rehabilitation. Int J Rehabil Res. 2017;40(3):215\u20139. https:\/\/doi.org\/10.1097\/MRR.0000000000000229.","journal-title":"Int J Rehabil Res"},{"key":"4682_CR19","doi-asserted-by":"publisher","unstructured":"Marfella R, Prattichizzo F, Sardu C, Rambaldi PF, Fumagalli C, Marfella LV, et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23(1):10. https:\/\/doi.org\/10.1186\/s12933-023-02118-6.","DOI":"10.1186\/s12933-023-02118-6"},{"key":"4682_CR20","doi-asserted-by":"publisher","unstructured":"Vitale G, Romano G, Di Franco A, Caccamo G, Nugara C, Ajello L, Storniolo S, Sarullo S, Agnese V, Giallauria F, et al. Early effects of Sacubitril\/Valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction. J Clin Med. 2019;8(2). https:\/\/doi.org\/10.3390\/jcm8020262.","DOI":"10.3390\/jcm8020262"},{"key":"4682_CR21","doi-asserted-by":"publisher","unstructured":"Bozkurt B, Fonarow GC, Goldberg LR, Guglin M, Josephson RA, Forman DE, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454\u201369. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.030.","DOI":"10.1016\/j.jacc.2021.01.030"},{"issue":"6","key":"4682_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368\u201378. https:\/\/doi.org\/10.1038\/nrcardio.2016.25.","journal-title":"Nat Rev Cardiol"},{"key":"4682_CR23","doi-asserted-by":"publisher","first-page":"105573","DOI":"10.1016\/j.phrs.2021.105573","volume":"169","author":"J Bao","year":"2021","unstructured":"Bao J, Kan R, Chen J, Xuan H, Wang C, Li D, Xu T. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials. Pharmacol Res. 2021;169:105573. https:\/\/doi.org\/10.1016\/j.phrs.2021.105573.","journal-title":"Pharmacol Res"},{"issue":"9","key":"4682_CR24","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","volume":"23","author":"G Savarese","year":"2021","unstructured":"Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, Fonarow GC, Vaduganathan M, Coats A. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail. 2021;23(9):1499\u2013511. https:\/\/doi.org\/10.1002\/ejhf.2271.","journal-title":"Eur J Heart Fail"},{"key":"4682_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003118","author":"J Tang","year":"2024","unstructured":"Tang J, Wang P, Liu C, Peng J, Liu Y, Ma Q. Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis. Chin Med J (Engl. 2024. https:\/\/doi.org\/10.1097\/CM9.0000000000003118.","journal-title":"Chin Med J (Engl"},{"issue":"9","key":"4682_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jacc.2024.01.002","volume":"83","author":"DL Mann","year":"2024","unstructured":"Mann DL, Nicolas J, Claggett B, Miao ZM, Granger CB, Kerkar P, K\u00f8ber L, Lewis EF, McMurray J, Maggioni AP, et al. Angiotensin Receptor-Neprilysin Inhibition in patients with STEMI vs NSTEMI. J Am Coll Cardiol. 2024;83(9):904\u201314. https:\/\/doi.org\/10.1016\/j.jacc.2024.01.002.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"4682_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40261-020-00908-4","volume":"40","author":"D Acanfora","year":"2020","unstructured":"Acanfora D, Scicchitano P, Acanfora C, Maestri R, Goglia F, Incalzi RA, Bortone AS, Ciccone MM, Uguccioni M, Casucci G. Early initiation of Sacubitril\/Valsartan in patients with chronic heart failure after acute decompensation: A case series analysis. Clin Drug Investig. 2020;40(5):493\u2013501. https:\/\/doi.org\/10.1007\/s40261-020-00908-4.","journal-title":"Clin Drug Investig"},{"key":"4682_CR28","doi-asserted-by":"publisher","unstructured":"Goyal P, Gorodeski EZ, Marcum ZA, Forman DE. Cardiac rehabilitation to optimize medication regimens in heart failure. Clin Geriatr Med. 2019;35(4):549\u201360. https:\/\/doi.org\/10.1016\/j.cger.2019.06.001.","DOI":"10.1016\/j.cger.2019.06.001"},{"key":"4682_CR29","doi-asserted-by":"publisher","unstructured":"Jafri SH, Hushcha P, Dorbala P, Bousquet G, Lutfy C, Mellett L, et al. Use of optimal medical therapy in patients with cardiovascular disease undergoing cardiac rehabilitation. Curr Probl Cardiol. 2024;49(1 Pt A):102058. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102058.","DOI":"10.1016\/j.cpcardiol.2023.102058"},{"issue":"5","key":"4682_CR30","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.21037\/apm-21-877","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen C, Wu X, Li Y, Peng Y. Study on the application effect of Bisoprolol combined with sacubitril Valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). Ann Palliat Med. 2021;10(5):5455\u201361. https:\/\/doi.org\/10.21037\/apm-21-877.","journal-title":"Ann Palliat Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04682-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04682-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04682-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:56:41Z","timestamp":1743739001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04682-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4682"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04682-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Sixth Affiliated Hospital of Guangxi Medical University (YLSY-IRB-SR-2021035) and conducted in accordance with the Declaration of Helsinki. All procedures were performed in accordance with ethical standards. Written consent was obtained from all participants after they had been informed of the objectives, benefits, medical items and confidentiality agreement regarding their personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}